ZNRF2P3

Across TCGA pan-cancer cohorts, ZNRF2P3 RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of ZNRF2P3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ZNRF2P3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ZNRF2P3 is over-expressed in tumor, although a few such as LUAD and LUSC show the opposite, repressed pattern.

KIRC, LUAD, and LUSC are the cancer types where ZNRF2P3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNRF2P3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.064	.009	6	view →
LUAD	Female	All	−0.217	<.001	5	view →
LUSC	All	All	−0.104	.001	5	view →
HNSC	All	IV	+0.058	.030	3	view →
THCA	Male	IV	−0.310	.003	2	view →
BRCA	All	III,IV	+0.035	.042	2	view →
KICH	All	All	−0.115	.041	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

ZNRF2P3–KIRC

Open the KIRC breakdown →